Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$737B
53.69
$15.29
0.47
$5.80
0.73%
Price and volume
Market cap
$737B
Beta
0.47
52-week high
$935.63
52-week low
$623.78
Average daily volume
3.5M
Dividend rate
$5.80
Financial strength
Current ratio
1.278
Quick ratio
0.512
Long term debt to equity
186.686
Total debt to equity
217.891
Dividend payout ratio (TTM)
36.46%
Interest coverage (TTM)
25.14%
Profitability
EBITDA (TTM)
24,775.1
Gross margin (TTM)
82.64%
Net profit margin (TTM)
25.91%
Operating margin (TTM)
43.40%
Effective tax rate (TTM)
18.15%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
16.72%
Return on equity (TTM)
86.29%
Valuation
Price to earnings (TTM)
53.689
Price to revenue (TTM)
13.84
Price to book
40.3
Price to tangible book (TTM)
111.67
Price to free cash flow (TTM)
1,337.475
Free cash flow yield (TTM)
0.07%
Free cash flow per share (TTM)
0.614
Dividend yield (TTM)
0.71%
Forward dividend yield
0.73%
Growth
Revenue change (TTM)
36.83%
Earnings per share change (TTM)
88.31%
3-year revenue growth (CAGR)
22.36%
10-year revenue growth (CAGR)
10.50%
3-year earnings per share growth (CAGR)
34.61%
10-year earnings per share growth (CAGR)
23.01%
3-year dividend per share growth (CAGR)
15.23%
10-year dividend per share growth (CAGR)
10.96%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Bulls say / Bears say
The US FDA approved Inluriyo for advanced breast cancer after a late-stage trial showed a 38% reduction in disease progression or death, broadening Lilly’s oncology portfolio and near-term revenue potential (Reuters)
Analysts expect Lilly to report Q2 earnings of $5.57 per share on $14.71 billion in revenue, driven by strong sales of market-leading weight-loss drug Zepbound and diabetes treatment Mounjaro (Reuters)
Orforglipron, Lilly’s oral GLP-1 obesity candidate, outperformed Novo’s Rybelsus in recent head-to-head trials and is forecast to achieve up to $10 billion in peak annual sales with global filings planned imminently (Reuters)
Lilly halted its mid-stage bimagrumab trial aimed at preserving muscle mass alongside its blockbuster Zepbound, reflecting potential pipeline setbacks and intensifying competition in obesity adjunct therapies (Reuters)
A federal appeals court upheld a $183.7 million Medicaid fraud judgment against Lilly for underreporting drug price increases, underscoring significant legal liabilities and reputational risks (Reuters)
Novo Nordisk expects an FDA decision on its oral obesity candidate later this year, posing a direct competitive threat that could cap orforglipron’s market penetration (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $737B as of October 25, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 53.69 as of October 25, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of October 25, 2025, the dividend rate is $5.8 and the yield is 0.73%. Eli Lilly has a payout ratio of 36.46% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment date is unconfirmed.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.